CLAIMS

1. ~~A method of treating an anxiety disorder in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a therapeutically effective amount~~Use of riluzole, ~~or~~ a pharmaceutically acceptable salt or prodrug thereof in the manufacture of a medicament for treating an anxiety disorder in a patient in need thereof,

wherein the medicament is in the form of an oral solid molded fast-dispersing dosage form in order to provide a reduction of at least 10 Visual Analogue Scale (VAS) points as compared to administration of a placebo,

wherein the oral solid molded fast-dispersing dosage form comprises 50-70 weight% riluzole, pharmaceutically acceptable salt or prodrug thereof, 10-30 weight% fish gelatin, and 10-20 weight% of a filler, and

wherein the medicament provides an enhancement in memory of the patient.

2. The use~~method~~ of claim 1, wherein the dosage of riluzole in the oral solid molded fast-dispersing dosage form~~tablet~~ is from 20 to 50 mg.

3. The use~~method~~ of claim 2, wherein the dosage of riluzole in the oral solid molded fast-dispersing dosage form~~tablet~~ is about 35 mg.

4. The use~~method~~ of claim 1, wherein the ~~administration~~ medicament provides a reduction of at least 12 VAS points.

5. The use~~method~~ of claim 4, wherein the medicament ~~administration~~ provides a reduction of at least 14 VAS points.

6. The use~~method~~ of claim 1, wherein the medicament ~~administration~~ provides a reduction of from about 10 to 25 VAS points.

7. The use~~method~~ of claim 1, wherein the medicament ~~administration~~ provides a mean VAS Score of from about 49 to 60.

8. The use~~method~~ of claim 7, wherein the medicament ~~administration~~ provides a mean VAS Score of from about 52 to 58.


9. The usemethod of claim 1, wherein the disease is social anxiety disorder (SAD).

~~10. The method of claim 1 which provides an enhancement in memory of the patient.~~

101. The usemethod of claim 1, wherein the oral solid molded fast-dispersing dosage form further comprises ~~from about 50-70 weight% riluzole, pharmaceutically acceptable salt or prodrug thereof, about 10-30 weight% fish gelatin, about 10-20 weight% of a filler, and~~ 0.1-5.0 weight% of a flavorant.

112. The method of claim 111, wherein the filler is mannitol.


123. The method of claim 1, wherein the riluzole prodrug has the following formula:



and pharmaceutically acceptable salts thereof, wherein:

R_{23} is selected from the group consisting of H, CH_3, CH_2CH_3, $CH_2CH_2CH_3$, CH_2CCH, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2OH, CH_2OCH_2Ph, $CH_2CH_2OCH_2Ph$, $CH(OH)CH_3$, CH_2Ph, CH_2(cyclohexyl), CH_2(4-OH-Ph), $(CH_2)_4NH_2$, $(CH_2)_3NHC(NH_2)NH$, CH_2(3-indole), CH_2(5-imidazole), CH_2CO_2H, $CH_2CH_2CO_2H$, CH_2CONH_2, and $CH_2CH_2CONH_2$.

134. The method of claim 123, wherein the riluzole prodrug has the following formula:



.

~~15. A kit for treating a disease in a patient, the kit comprising:~~

~~(a) a pharmaceutical composition comprising a therapeutically effective amount of riluzole, or a pharmaceutically acceptable salt thereof in the oral solid molded fast dispersing tablet; and~~

~~(b) instructions for administering the pharmaceutical composition; wherein the therapeutically effective amount provides a reduction of at least 10 VAS points as compared to administration of a placebo.~~